Dopamine Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

Dopamine Agonists are drugs that act upon Dopamine receptors located in the body, specifically in the brain, and activate them by mimicking the action of natural dopamine. Dopamine plays a dual role in our body by acting as a neurotransmitter as well as a neurohormone. It plays a role in body movements, memory, and pleasurable rewards and motivation. It is secreted during pleasurable situations, and therefore, dopamine is known to influence a  person’s mood and feelings. A disbalance of dopamine levels in the brain has been associated with many behavioral and mental disorders like Anxiety, Dementia, Parkinson’s disease (PD), and others. Conditions like Parkinson’s disease (PD) are characterized by low dopamine levels in the central nervous system. Hence, agonists are used to treat the symptoms of the disease and slow its progression. Research is being conducted globally to discover new and novel molecules to be used as dopamine agonists that may increase the level of dopamine in dopamine-deficient patients. The development and launch of new products will thus increase the market’s revenue in the forecasted years. According to the International Parkinson and Movement Disorder Society 2023 report, an estimated 9.4 million people globally are living with PD in 2020. According to the Parkinson’s Foundation 2023 report, nearly 1 million US residents have PD, while approximately 90,000 people are diagnosed yearly. The number of patients suffering from PD is expected to reach 1.2 million by 2030 in the USA. The prevalence of the disease has been rising continuously for many decades, which marks an opportunity for the market players.

A number of these inhibitors are in the market, while many are in ongoing clinical trials. 48 companies have various products in their pipelines, with 55 products in various stages of clinical trials. 9 products in Phase 4, 10 in Phase 3, 13 in Phase 2, and 9 in Phase 1 of the clinical trials.

Key Developments of Dopamine Agonists

  • In August 2021, FDA approved Xywav (calcium/magnesium/potassium/sodium oxybates) along with Orphan drug designation for the treatment of adults with Idiopathic Hypersomnia (IH).
  • In February 2021, FDA approved Gocovri (amantadine ER) as an adjuvant treatment to Levodopa/Carbidopa in Parkinson’s disease patients experiencing OFF episodes.
  • In January 2021, European Commission (EU) granted Orphan drug designation to Xywav (calcium/magnesium/potassium/sodium oxybates) for the treatment of adults with Idiopathic Hypersomnia (IH).
  • In July 2020, FDA approved Xywav (calcium/magnesium/potassium/sodium oxybates) for the treatment of people above 7 years with Cataplexy or Excessive Daytime Sleepiness associated with Narcolepsy.

Approved molecules of Dopamine Agonists

  • Duodopa (levodopa/carbidopa intraduodenal gel infusion)
  • Permax (pergolide)
  • Cycloset (bromocriptine)
  • Gocovri (amantadine ER)
  • Xywav (calcium/magnesium/potassium/sodium oxybates)
  • Akineton (biperiden)
  • Kynmobi (apomorphine sublingual film)
  • Osmolex ER (amantadine ER)
  • Apofin (apomorphine)

Drugs in the Pipeline of Dopamine Agonists

  • dexpramipexole (KNS-760704)
  • Inbrija (levodopa inhalation powder)
  • APO-go (apomorphine continuous subcutaneous infusion)
  • levodopa/carbidopa high dose (ND0612H)
  • Rytary (levodopa/carbidopa extended-release capsule)
  • foscarbidopa/foslevodopa (ABBV-951)
  • levodopa/carbidopa ER (WD-1603)
  • Accordion Pill carbidopa/levodopa CR (carbidopa/levodopa CR)
  • levodopa/carbidopa extended-release capsule (IPX203)
  • apomorphine inhalational (VR 040)
  • dopastatin (TBR-760)
  • AM006
  • Cerebral dopamine neurotrophic factor (CDNF)
  • DopaFuse (levodopa/carbidopa continuous-release)
  • Lecigon (carbidopa/levodopa/entacapone)
  • Trivastal (piribedil)
  • carbidopa ester transdermal (ND0611)
  • levodopa prodrug (XP21279)
  • levodopa/carbidopa low dose (ND0612L)
  • Alcover (sodium oxybate)
  • CLR4001
  • Infudopa IntraV (levodopa/carbidopa IV)
  • Infudopa SubC (levodopa/carbidopa SC)
  • SER-214
  • Sirio (carbidopa/melevodopa)
  • XC130
  • apomorphine intranasal
  • deuterated sodium oxybate (JZP-386)
  • fencamfamine prodrug (PRX-P4-003)
  • levodopa/carbidopa CR (DM 1992)
  • rotigotine microspheres (LY03009)

Clinical Activity and Developments of Dopamine Agonists

As of June 2023, 48 companies have approximately 55 products for 285 diseases. For these diseases, 104 trials are being conducted by players globally. For instance,

  • In January 2023, Ain Shams University completed a Phase 4 clinical trial to study the impact of preoperative aripiprazole on postoperative analgesia in laparoscopic hysterectomy
  • In September 2022, Luye Pharma Group Ltd completed a Phase 3 clinical trial to evaluate the effectiveness and safety of ly03003 in patients with early primary pd
  • In May 2022, Otsuka Pharmaceutical Development & Commercialization, Inc. completed a Phase 4 clinical trial to assess the effects of engagement of flexible-dose Brexpiprazole as adjuvant therapy for treating adults with Major Depressive Disorders.

Molecule name

Number of studies

Duodopa (levodopa/carbidopa intraduodenal gel infusion)


Permax (pergolide)


Cycloset (bromocriptine)


Gocovri (amantadine ER)


Xywav (calcium/magnesium/potassium/sodium oxybates)


Target Indication Analysis of Dopamine Agonists

Drugs like Duodopa (levodopa/carbidopa intraduodenal gel infusion) and Permax (pergolide) Have been approved by the FDA and other regulatory agencies for the treatment of various indications.  These are indicated for use alone or in combination with other therapies to derive maximum output. Duodopa is indicated for treating patients with advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and dyskinesia or hyperkinesia. Permax is indicated as an adjuvant treatment to levodopa/carbidopa for the management of signs and symptoms of Parkinson’s disease. Other indications are which Dopamine Agonists are used are Basal Ganglia disorders, Mood disorders, Dyskinesia, Psychotic disorders, Dementia, Dyssomnia, and many others. 

Frequently Asked Questions

Duodopa (levodopa/carbidopa intraduodenal gel infusion), Permax (pergolide), Cycloset (bromocriptine), and Gocovri (amantadine ER) are some of the molecules approved by various regulatory agencies.

These are used to treat Parkinson’s disease, Mood disorders, Dyskinesia, Psychotic disorders, Dementia, Dyssomnia, and others.

Knopp Biosciences, Biogen, Acorda Therapeutics, Eli Lilly, and Bausch Health are some of the major market players for Dopamine agonists.

Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to various disorders like Parkinson’s disease (PD), Idiopathic Hypersomnia (IH) are the key opportunities for Dopamine agonists in the market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Knopp Biosciences
  • Biogen
  • Acorda Therapeutics
  • Eli Lilly
  • Bausch Health
  • Supernus Pharma
  • Stada
  • Kyowa Kirin
  • Endo Pharmaceuticals
  • Amneal Pharmaceuticals
  • Jazz Pharmaceuticals
  • Abbvie
  • Aquestive Therapeutics
  • Bial
  • China Nt Pharma
  • Indaptus Therapeutics
  • Vectura Group Ltd
  • Tiburio Therapeutics
  • Kissei Pharmaceuticals
  • Affamed Therapeutics
  • Herantis Pharma
  • Chiesi Farmaceutici
  • Synagile
  • Lobsor Pharmaceuticals
  • Les Laboratories Servier
  • Mitsubishi Tanabe
  • Arbor Pharmaceuticals
  • D&A Pharma
  • Juste Group
  • Clera
  • Dizlin Pharmaceuticals
  • Serina Therapeutics
  • Ligand Pharmaceuticals
  • Xoc Pharmaceuticals
  • Sun Pharma
  • Praxis Bioresearch
  • Assertio Therapeutics
  • Luye Group

Adjacent Markets